Endothelin 1(human) peptide

Endothelin 1(human) peptide

• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

Batch to batch variation of the purity

H-CSCSSLMDKECVYFCHLDIIW-OH

H-Cys-Ser-Cys-Ser-Ser-Leu-Met-Asp-Lys-Glu-Cys-Val-Tyr-Phe-Cys-His-Leu-Asp-Ile-Ile-Trp-OH

21

95.35%

C₁₀₉H₁₅₉N₂₅O₃₂S₅

2491.89

Synthetic

Powder

Endothelin-1 is one of three isoforms of human endothelin (ET-1). It is a potent vasoconstrictor that is expressed by many cell types, with the vascular endothelium being most prominent. ET-1 is also produced by many tissues, including kidney, brain and lung among others. Antagonists of ET-1 receptors are used to treat pulmonary hypertension by inhibiting pulmonary vascular constriction thereby decreasing pulmonary vascular resistance.

Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual: Handling and Storage of Synthetic Peptides

Trifluoroacetic acid (TFA) has a significant impact on peptides due to its role in the peptide synthesis process.

TFA is essential for the protonation of peptides that lack basic amino acids such as Arginine (Arg), Histidine (His), and Lysine (Lys), or ones that have blocked N-termini. As a result, peptides often contain TFA salts in the final product.

TFA residues, when present in custom peptides, can cause unpredictable fluctuations in experimental data. At a nanomolar (nM) level, TFA can influence cell experiments, hindering cell growth at low concentrations (as low as 10 nM) and promoting it at higher doses (0.5–7.0 mM). It can also serve as an allosteric regulator on the GlyR of glycine receptors, thereby increasing receptor activity at lower glycine concentrations.

In an in vivo setting, TFA can trifluoroacetylate amino groups in proteins and phospholipids, inducing potentially unwanted antibody responses. Moreover, TFA can impact structure studies as it affects spectrum absorption.